97337 ⎘
Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF
#302ANTI-PD-L1 ANTIBODIES AND FUSION PROTEINS THEREOF
#303Compositions and Methods for Treating Cancer with Anti-CD19 Immunotherapy
#304Anti-VEGF protein compositions and methods for producing the same
#305Il-2 variants with reduced binding to IL-2 receptor alpha and uses thereof
#306Nucleic Acid Molecule Containing Incorporated Gene Encoding Fused Protein of Ligand and Protein Having Physiological Activity
#307METHODS AND COMPOSITIONS FOR ADOPTIVE CELL THERAPY
#308pH-triggered membrane peptide-mediated epitope tethering at cell surfaces
#309SIALIDASE-PD-1-ANTIBODY FUSION PROTEINS AND METHODS OF USE THEREOF
#310FUSION PROTEIN, AND PREPARATION METHOD AND USE THEREOF
#311Methods and compositions for dosing of allogeneic chimeric antigen receptor T cells
#312COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ANTI-CD19/CD20 IMMUNOTHERAPY
#313PROTEIN CONTAINING HETERODIMER ANTIBODY FC, AND PREPARATION METHOD THEREFOR
#314T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF
#315Antibody Immune Cell Inhibitor Fusion Proteins
#316Methods for treating diabetes, hepatitis, and/or inflammatory liver disease
#317RECOMBINANT PROTEIN TARGETING PD-1 AND TGFBETA
#318DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES
#319CAR Cells and Polyspecific Binding Molecules for Treating Solid Tumor
#320CHIMERIC IMMUNOGENIC POLYPEPTIDES
#321Use of Triplex CMV Vaccine in CAR T Cell Therapy
#322Chimeric antigen receptor comprising BCMA nanobody linked to a chimeric intracellular signaling domain
#323CHIMERIC ANTIGEN RECEPTOR COMPRISING NOVEL CO-STIMULATORY DOMAIN AND USE THEREOF
#324MODIFIED NK-92 CELLS FOR TREATING CANCER
#325GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
#326THERAPEUTIC MULTI-TARGETING CONSTRUCTS AND USES THEREOF
#327Chimeric antigen receptor for tumor targeting
#328Methods and compositions for modulating CAR-T activity
#329FULLY HUMAN ANTIBODY TARGETING CD5, AND FULLY HUMAN CHIMERIC ANTIGEN RECEPTOR (CAR) AND APPLICATION THEREOF
#330ENGINEERED CHIMERIC ANTIMICROBIAL AGENTS AGAINST GRAM-POSITIVE BACTERIA
#331POLYPEPTIDE COMPOSITIONS COMPRISING SPACERS
#332METHODS OF IDENTIFYING GAMMA DELTA T CELL-MODULATING AGENTS
#333ENGINEERED IPSC AND IMMUNE EFFECTOR CELLS FOR HETEROGENOUS TUMOR CONTROL
#334Antigen binding receptors specific for mutated Fc domains
#335Methods and Compositions for Reducing Immunosupression by Tumor Cells
#336TRANSCRIPTION ACTIVE COMPLEX TARGETING CANCER DRUG FROM VIRAL PROTEIN SEQUENCE
#337METHODS FOR CONTROLLED ACTIVATION AND/OR EXPANSION OF GENETICALLY ENGINEERED CELLS USING POLYETHYLENE GLYCOL (PEG) RECEPTORS
#338ANTI-TN-MUC1 CHIMERIC ANTIGEN RECEPTORS
#339DUAL-TARGETING CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS COMPRISING IL-13 AND CHLOROTOXIN FOR CANCER TREATMENT
#340CHIMERIC RECEPTORS AND METHODS OF USE THEREOF
#341BISPECIFIC RECOMBINANT PROTEIN AND USE THEREOF
#342SINGLE DOMAIN ANTIBODIES AGAINST CD33
#343CHIMERIC ANTIGEN RECEPTOR, REGULATORY CELLS AND METHODS OF USE
#344METHODS AND COMPOSITIONS FOR GENOMIC INTEGRATION
#345METHODS AND COMPOSITIONS FOR GENOMIC INTEGRATION
#346SYNTHETIC ADENOVIRUSES TARGETING BONE TISSUE AND USES THEREOF
#347FIBRONECTIN EXTRA DOMAIN B (EDB) -SPECIFIC CAR-T FOR CANCER
#348COMPOSITIONS AND METHODS FOR CHIMERIC ANTIGEN RECEPTOR (CAR)-MODIFIED CELL MODULATION
#349T CELL RECEPTOR-DEFICIENT CHIMERIC ANTIGEN RECEPTOR T-CELLS AND METHODS OF USE THEREOF
#350METHODS AND COMPOSITIONS FOR TREATING GLIOBLASTOMA
#351ONCOLYTIC HERPES SIMPLEX VIRUSES (HSV) EXPRESSING IMMUNOMODULATORY FUSION PROTEINS
#352CELL SECRETED MINIBODIES AND USES THEREOF
#353ANTI-IDIOTYPE COMPOSITIONS AND METHODS OF USE THEREOF
#354HUMANIZED ANTIBODY, CHIMERIC ANTIGEN RECEPTOR, NUCLEIC ACID, VECTOR, CELL AND USE
#355Anti-VEGF protein compositions and methods for producing the same
#356IL-21 polypeptides and targeted constructs
#357NEIL2 PROTEIN THERAPY FOR TREATMENT OF VIRAL INFECTION
#358CHIMERIC ANTIGEN RECEPTORS TARGETED TO PSCA
#359NANOBODY BASED IMAGING AND TARGETING OF ECM IN DISEASE AND DEVELOPMENT
#360CYTOKINE FUSION PROTEINS, AND THEIR PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS
#361SYSTEMS FOR IN VIVO MONITORING OF IMMUNE CELLS IN PATIENTS UNDERGOING CELLULAR IMMUNOTHERAPY
#362ENGINEERED T CELLS, AND PREPARATION AND USE THEREOF
#363Chimeric Antigen Receptor
#364Methods and compositions for transducing lymphocytes and regulating the activity thereof
#365NOVEL ANTI-LILRB4 ANTIBODIES AND DERIVATIVE PRODUCTS
#366IL-21 polypeptides and targeted constructs
#367CHIMERIC ANTIGEN RECEPTOR (CAR) WITH CD28 TRANSMEMBRANE DOMAIN
#368OPTIMIZATION OF CHIMERIC ANTIGEN RECEPTOR
#369ANTI-TFR:GAA AND ANTI-CD63:GAA INSERTION FOR TREATMENT OF POMPE DISEASE
#370PRODUCTION OF ANTIGEN-SPECIFIC T-CELLS
#371Use of CD2/5/7 Knock-Out Anti-CD2/5/7 Chimeric Antigen Receptor T cells Against T Cell Lymphomas and Leukemias
#372CD22 ANTIBODY AND APPLICATION THEREOF
#373SINGLE-DOMAIN ANTIBODIES THAT BIND SARS-COV-2
#374Anti-VEGF protein compositions and methods for producing the same
#375CHIMERIC MOLECULES PROVIDING TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY
#376HYBRID PROMOTERS, VECTORS CONTAINING SAME AND METHODS OF USE
#377PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS
#378METHODS AND COMPOSITIONS RELATING TO EX VIVO CULTURE AND MODULATION OF T CELLS
#379PHARMACEUTICAL COMPOSITION COMPRISING CELL EXPRESSING CHIMERIC RECEPTOR
#380METHODS AND COMPOSITIONS FOR TREATING GLIOBLASTOMA
#381REGULATORY T CELL EPITOPES
#382Bi-Peptide with Affinity to Extracellular Matrix Proteins or Cells and to Growth Factors for Tissue Healing and Regeneration
#383CD28 COMPOSITIONS AND METHODS FOR CHIMERIC ANTIGEN RECEPTOR THERAPY
#384CHIMERIC ANTIGEN RECEPTORS (CAR) AND METHODS FOR MAKING AND USING THE SAME
#385Glycan-dependent Immunotherapeutic Molecules
#386Methods of Modulating Expression of Target Nucleic Acid Sequences in A Cell
#387COMPOSITIONS AND METHODS FOR IN VIVO GENERATION OF CAR EXPRESSING CELLS
#388MATERIALS AND METHODS FOR ENGINEERING CELLS AND USES THEREOF IN IMMUNO-ONCOLOGY
#389CELL/GENE THERAPIES TARGETING MAGE-A4 PEPTIDE
#390Conjugates for Targeted Cell Surface Editing
#391BI-FUNCTIONAL CHIMERIC PROTEINS AND USES THEREOF
#392CHIMERIC ANTIGEN RECEPTOR CELLS TARGETING ROBO1, PREPARATION METHOD AND USE THEREOF
#393COMPOSITIONS AND METHODS TO TARGET ANTI-TNF-ALPHA ANTIBODY
#394BINDING PROTEINS RECOGNIZING SARS-COV-2 ANTIGENS AND USES THEREOF
#395Interferon-associated antigen binding proteins and uses thereof
#396TECHNIQUE FOR PREPARING UNIVERSAL HUMANISED CAR19-DNT CELLS AND APPLICATION THEREFOR
#397FUSION PROTEIN COMPRISING A BLOOD-BRAIN BARRIER (BBB)-CROSSING SINGLE DOMAIN ANTIBODY FC5, AN IMMUNOGLOBULIN FC FRAGMENT AND A BETA-AMYLOID BINDING POLYPEPTIDE (ABP)
#398Hepatitis B vaccines and uses of the same
#399CANINE AND FELINE INDUCIBLE EXPRESSION CONSTRUCTS FOR GENE THERAPY APPLICATIONS
#400Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer, infections and autoimmune disorders
#401IL-1 RECEPTOR ANTAGONIST (IL-1 RA) FUSION PROTEINS BINDING TO THE EXTRACELLULAR MATRIX
#402Anti-VEGF protein compositions and methods for producing the same
#403MODULATORS OF THE IMMUNE ESCAPE MECHANISM FOR UNIVERSAL CELL THERAPY
#404EPHA3 AND MULTI-VALENT TARGETING OF TUMORS
#405CHIMERIC ANTIGEN RECEPTOR CELL
#406ANTI-CD22 SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC CONSTRUCTS
#407CHIMERIC ANTIGEN RECEPTORS WITH ENHANCED NFKB SIGNALING
#408CYTOKINE CONJUGATES
#409PERSONALIZED IMMUNOTHERAPY AGAINST SEVERAL NEURONAL AND BRAIN TUMORS
#410Fusion Proteins Having a Toxin and Cancer Marker, Nanoparticles, and Uses Related Thereto
#411TGFßR2 EXTRACELLULAR DOMAIN TRUNCATED MOLECULE, FUSION PROTEIN OF TGFßR2 EXTRACELLULAR DOMAIN TRUNCATED MOLECULE AND ANTI-EGFR ANTIBODY, AND ANTI-TUMOR USE OF FUSION PROTEIN
#412Fusion molecules and IL-15 variants
#413Coronavirus vaccine comprising a mosaic protein
#414BCMA chimeric antigen receptors and uses thereof
#415Chimeric antigen receptors against multiple HLA-G isoforms
#416DOCK TAG SYSTEM
#417IMMUNE CELLS WITH INCREASED GLYCOLYTIC FLUX
#418SLAMF7 CARS
#419CHIMERIC ANTIGEN RECEPTOR CONSTRUCTS AND THEIR USE IN CAR-T CELLS
#420Lysosomal Targeting Peptides and Uses Thereof
#421COMPOSITIONS AND METHODS FOR TARGETED PROTEIN STABILIZATION BY REDIRECTING ENDOGENOUS DEUBIQUITINASES
#422Anti-CD30 Antibodies and Methods for Treating CD30+ Cancer
#423HUMANIZED CD19 ANTIBODY AND USE THEREOF
#424Anti-VEGF protein compositions and methods for producing the same
#425TISSUE TARGETED IMMUNOTOLERANCE WITH PD-1 AGONISTS OR IL-2 MUTEINS
#426Cell
#427ENZYME-MEDIATED DEPLETION OF ADENOSINE AND/OR METHYLTHIOADENOSINE
#428Enhanced Chimeric Antigen Receptor Cells in Hypoxic Tumor Microenvironment
#429COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS
#430PD-L1-SPECIFIC ANTIBODY AND ANTI-PD-L1-CAR-T CELLS
#431METHODS AND MATERIALS FOR TREATING CANCER
#432BBB-TARGETED GAA DELIVERED AS GENE THERAPY TREATS CNS AND MUSCLE IN POMPE DISEASE MODEL MICE
#433TREATMENT OF CANCER USING A CD123 CHIMERIC ANTIGEN RECEPTOR
#434Chimeric Antigen Receptor (CAR) Comprising A CD19-Binding Domain
#435REGENERATIVE CAR-T CELLS
#436PD1-CD70 FUSION PROTEIN AND METHODS OF USE THEREOF
#437METHOD FOR OBTAINING CAR-NK CELLS
#438Tissue-homing peptide conjugates and methods of use thereof
#439OVERCOMING THE TUMOR MICROENVIRONMENT FOR CELL THERAPY BY TARGETING MYELOID DERIVED SUPPRESSOR CELLS THROUGH A TRAIL-R2 SPECIFIC RECEPTOR
#440RECOMBINANT POLYPEPTIDES FOR PROGRAMMING EXTRACELLULAR VESICLES
#441SERINE PROTEASE MOLECULES AND THERAPIES
#442ACE2 RECEPTOR POLYMORPHISMS AND VARYING SUSCEPTIBILITY TO SARS-COV-2, METHODS FOR DIAGNOSIS AND TREATMENT
#443ROR1-SPECIFIC ANTIGEN BINDING MOLECULES
#444ENGINEERED CENTRAL NERVOUS SYSTEM COMPOSITIONS
#445CHIMERIC ANTIGEN RECEPTORS TARGETING CLAUDIN-3 AND METHODS FOR TREATING CANCER
#446CHIMERIC RECEPTOR POLYPEPTIDES AND USES THEREOF
#447RECOMBINANT POLYPEPTIDES FOR MEMBRANE FUSION AND USES THEREOF
#448COMPOSITIONS AND METHODS FOR CORONAVIRUS DETECTION
#449EXOSOME DELIVERY OF CANCER THERAPEUTICS
#450BCMA chimeric antigen receptors and uses thereof
#451A TARGETING MODULE COMPRISING PD-L1 AND/OR PD-L2 FOR USE IN A METHOD FOR STIMULATING A CHIMERIC ANTIGEN RECEPTOR MEDIATED IMMUNE RESPONSE IN A MAMMAL
#452Modified TNF-α antibodies and uses thereof
#453METHODS FOR PREVENTING, REVERSING OR TREATING A COVID-19 INFECTION
#454Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
#455PEPTIDES HAVING SPECIFICITY FOR THE LUNGS
#456METHODS OF GENERATING CELLS
#457USE OF TRANS-SIGNALING APPROACH IN CHIMERIC ANTIGEN RECEPTORS
#458ANTI-BCMA ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS
#459DONOR REPAIR TEMPLATES MULTIPLEX GENOME EDITING
#460METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS
#461COMPOSITIONS AND METHODS FOR MEMBRANE PROTEIN STRUCTURE DETERMINATION
#462CHIMERIC ANTIGEN RECEPTORS TARGETING CD37
#463VIRUS-SPECIFIC IMMUNE CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORS
#464HOMING PEPTIDE-GUIDED DECORIN CONJUGATES FOR USE IN TREATING EPIDERMOLYSIS BULLOSA
#465GPC3 CAR- T CELLS SECRETING IL-18 AND METHODS OF MAKING AND USING THE SAME
#466CD229 Car T Cells And Methods Of Use Thereof
#467Neoepitope immunotherapy with APC targeting unit
#468TAILORED HYPOIMMUNE NANOVESICULAR DELIVERY SYSTEMS FOR CANCER TUMORS, HEREDITARY AND INFECTIOUS DISEASES
#469AFFINITY MATURED AND HUMANIZED BINDING DOMAINS TARGETING ROR2
#470ALL-IN ONE VECTOR FOR CAR AND THERAPEUTIC EFFECTOR MOLECULE
#471Methods and compositions for genomic integration
#472Engineered immune cell and use thereof
#473GLYPICAN-2-BINDING MOIETIES, CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
#474GENE THERAPY
#475ENGINEERED REGULATORY T CELL
#476NPP1 FUSION PROTEINS
#477CD7-CAR-T CELL AND PREPARATION AND APPLICATION THEREOF
#478ANTIBODIES AGAINST PD-L1 AND METHODS OF USE THEREOF
#479D-DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF
#480CHIMERIC RECEPTORS TO FLT3 AND METHODS OF USE THEREOF
#481Compositions and Methods for Gene Editing
#482CHIMERIC STIMULATORY RECEPTORS AND METHODS OF USE IN T CELL ACTIVATION AND DIFFERENTIATION
#483Anti-VEGF protein compositions and methods for producing the same
#484SYNERGISTIC AND TARGETING COMPOSITIONS FOR TREATMENT OF ARTERIAL AND VENOUS THROMBOSIS
#485Immune synapse-stabilizing chimeric antigen receptor (CAR) T cell
#486ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION
#487COMPOSITIONS AND METHODS FOR GENE EDITING
#488QUANTITATIVE CONTROL OF ACTIVITY OF ENGINEERED CELLS EXPRESSING SPYCATCHER AND SPYTAG UNIVERSAL IMMUNE RECEPTORS
#489Fractal Combination Therapy
#490Compositions and methods for delivery of nucleic acids to cells
#491FUSION PROTEINS AND USES THEREOF
#492Personalized immunotherapy against several neuronal and brain tumors
#493Compositions and methods for delivery of nucleic acids to cells
#494ANTI-IL1RAP ANTIBODIES
#495Methods to spatially profile protease activity in tissue and sections
#496PDE5 compositions and methods for immunotherapy
#497ANTI-GPC3 SINGLE-CHAIN ANTIBODY-CONTAINING CAR
#498Anti-VEGF protein compositions and methods for producing the same
#499Methods and compositions for genomic integration
#500HOMODIMERIC PROTEIN CONSTRUCTS
#501TREATMENT OF MUCOPOLYSACCHARIDOSIS IVA
#502SPLIT CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE
#503Chimeric molecules providing targeted costimulation for adoptive cell therapy
#504NOVEL DOMINANT NEGATIVE FAS POLYPEPTIDES, CELLS COMPRISING THEREOF AND USES THEREOF
#505TARGETED PROTEIN CONTRAST AGENTS, METHODS OF MAKING, AND USES THEREOF
#506HUMAN IgG Fc DOMAIN VARIANTS WITH IMPROVED EFFECTOR FUNCTION
#507RECEPTORS PROVIDING TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY
#508FUSOKINES INVOLVING CYTOKINES WITH STRONGLY REDUCED RECEPTOR BINDING AFFINITIES
#509Chimeric antigen receptor and methods of use thereof
#510CONSTRUCTS SPECIFICALLY RECOGNIZING GLYPICAN 3 AND USES THEREOF
#511ENGINEERED T CELLS
#512Chimeric antigen receptors targeting CD70
#513Anti-VEGF protein compositions and methods for producing the same
#514M13 PHAGE BASED GENE THERAPY PLATFORM
#515BCMA-binding antibody and use thereof
#516MULTISPECIFIC NANOBODIES CHIMERIC ANTIGEN RECEPTOR AND T-CELL ENGAGER, NUCLEIC ACID, EXPRESSING CELL THEREOF, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, AND METHOD FOR INHIBITING PROLIFERATION OF TUMOR CELL
#517BCG CAR CONSTRUCTS AND METHODS OF THEIR MANUFACTURE AND USE
#518SORTILIN BINDING CONJUGATE COMPOUNDS, COMPOSITIONS AND USES THEREOF FOR TREATING CANCER
#519Compositions and methods for delivery of nucleic acids to cells
#520METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING A SAGE1-RELATED CONDITION
#521COMPOSITIONS AND METHODS FOR THE CYTOPLASMIC DELIVERY OF ANTIBODIES AND OTHER PROTEINS
#522Restimulation of cryopreserved tumor infiltrating lymphocytes
#523BLOCKING CHIMERIC ANTIGEN RECEPTORS FOR PREVENTION OF UNDESIRED ACTIVATION OF EFFECTOR AND REGULATORY IMMUNE CELLS
#524NEW ONCOLYTIC VIRUS PLATFORM TO TREAT CANCERS WITH MYXOMA VIRUS
#525Chimeric Antigen Receptor and Natural Killer Cells Expressing Same
#526CAR T CELLS WITH ENHANCED METABOLIC FITNESS
#527FUSION PROTEINS THAT FACILITATE CANCER CELL DESTRUCTION
#528MATERIALS AND METHODS FOR ENGINEERING CELLS AND USES THEREOF IN IMMUNO-ONCOLOGY
#529GPC3 BINDING MOLECULES
#530Chimeric antigen receptors targeting Fc receptor-like 5 and uses thereof
#531Receptors providing targeted costimulation for adoptive cell therapy
#532TRUNCATED NKG2D CHIMERIC RECEPTORS AND USES THEREOF IN NATURAL KILLER CELL IMMUNOTHERAPY
#533Chimeric antigen receptors, compositions and applications thereof
#534METHODS AND COMPOSITIONS FOR GENOMIC INTEGRATION
#535CHIMERIC TRANSCRIPTION FACTOR VARIANTS WITH AUGMENTED SENSITIVITY TO DRUG LIGAND INDUCTION OF TRANSGENE EXPRESSION IN MAMMALIAN CELLS
#536Antitumor peptide and use thereof
#537Antigen binding molecules specific for an anti-CD19 scFV
#538PROTEASE SWITCH FOR DUAL TARGETS CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY
#539NUCLEIC ACID CONSTRUCT THAT ENCODES CHIMERIC RHODOPSIN
#540IL2-BASED THERAPEUTICS AND METHODS OF USE THEREOF
#541CELL-TARGETING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT EFFECTORS AND CD8+ T-CELL EPITOPES
#542Compositions and Methods for Inhibiting T Cell Exhaustion
#543TARGETING PD-L1 ON TUMOR CELLS
#544Anti-VEGF protein compositions and methods for producing the same
#545Restimulation of cryopreserved tumor infiltrating lymphocytes
#546Anti-VEGF protein compositions and methods for producing the same
#547ALLOGENEIC CELL COMPOSITIONS AND METHODS OF USE
#548Restimulation of cryopreserved tumor infiltrating lymphocytes
#549Restimulation of cryopreserved tumor infiltrating lymphocytes
#550CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY
#551METHODS OF MAKING CELLULAR THERAPIES
#552Method of treating cancer by administering immune effector cells expressing a chimeric antigen receptor comprising a CD20 binding domain
#553TRANSGENE GENETIC TAGS AND METHODS OF USE
#554TMEM59 PROTEIN DIMER OR CHIMERIC EXPRESSION RECEPTOR IMPROVING T CELL FUNCTION
#555RESTIMULATION OF CRYOPRESERVED TUMOR INFILTRATING LYMPHOCYTES
#556Restimulation of cryopreserved tumor infiltrating lymphocytes
#557IMPROVING CAS NUCLEASE TARGET SPECIFICITY
#558CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE
#559DEFINED COMPOSITION GENE MODIFIED T-CELL PRODUCTS
#560FUSION POLYPEPTIDES BINDING ANTIBODY FC DOMAINS AND INTEGRIN AND METHODS OF USE
#561Therapeutic Biologic For Treatment Of Hepatocellular Carcinoma
#562Methods and compositions for reducing the immunogenicity of chimeric notch receptors
#563HUMAN ANTI-ANTXR CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF
#564METHODS AND COMPOSITIONS FOR GENOMIC INTEGRATION
#565CHIMERIC RECEPTORS TARGETING ADGRE2 AND/OR CLEC12A AND USES THEREOF
#566METHODS AND COMPOSITIONS FOR REDUCING THE IMMUNOGENICITY OF CHIMERIC NOTCH RECEPTORS
#567Personalized immunotherapy against several neuronal and brain tumors
#568Personalized immunotherapy against several neuronal and brain tumors
#569ADOPTIVE CELL THERAPY
#570COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS
#571Immunosuppressive antigen-specific chimeric antigen receptor Treg cells for prevention and/or treatment of autoimmune and alloimmune disorders
#572HUMANIZED BCMA ANTIBODY AND BCMA-CAR-T CELLS
#573CLEC9A BINDING AGENTS
#574CELL-TARGETING MOLECULES COMPRISING DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT EFFECTORS AND CD8+ T-CELL EPITOPES
#575Lysosomal Targeting Peptides and Uses Thereof
#576DNMT3A KNOCKOUT CAR T CELLS FOR ADOPTIVE IMMUNOTHERAPY
#577GLYCOPROTEIN MANUFACTURING PROCESS
#578CAR NKTs Expressing Artificial Micro RNA-Embedded shRNA for Downregulation of MHC Class I & II Expression
#579ENHANCED IMMUNE CELLS USING DUAL SHRNA AND COMPOSITION INCLUDING THE SAME
#580Enhanced immune cells using dual shRNA and composition including the same
#581Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies
#582ANTIGEN SPECIFIC CD19-TARGETED CAR-T CELLS
#583COMPOUND CHIMERIC ANTIGEN RECEPTOR (cCAR) TARGETING MULTIPLE ANTIGENS, COMPOSITIONS AND METHOD OF USE THEREOF
#584Methods of using low dose volume B-cell epitope compositions for inducing an antibody immune response in human subjects
#585Chimeric antigen receptors targeting B-cell maturation antigen
#586CONSTRUCTION OF CHIMERIC ANTIGEN RECEPTOR TARGETING CD20 ANTIGEN AND ACTIVITY IDENTIFICATION OF ENGINEERED T CELLS THEREOF
#587NOTCH RECEPTORS WITH MINIMAL LINKER
#588CD8-specific antibody constructs and compositions thereof
#589Methods of Activating and Proliferating Exhausted CD8 T Cells, CD8 T Cells with Enhanced Activity Prepared by the Same, and Uses Thereof
#590Combined Artificial Cell Death/Reporter System Polypeptide for Chimeric Antigen Receptor Cell and Uses Thereof
#591ANTIBODY CHEMICALLY INDUCED DIMERIZERS (AbCID) AS MOLECULAR SWITCHES AND USES THEREOF
#592High-Density Flagellin-Displaying Virus-Like Particle As Vaccine Carrier
#593Methods and compositions for modulating CAR-T activity
#594CD25 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
#595Compositions and Methods for Treating Cancer with Anti-CD19/CD22 Immunotherapy
#596ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS THAT TARGET TACI
#597CD33 TARGETED IMMUNOTHERAPIES
#598Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof
#599FUSION PROTEINS COMPRISING A BINDING PROTEIN AND AN INTERLEUKIN-15 POLYPEPTIDE HAVING A REDUCED AFFINITY FOR IL15Ra AND THERAPEUTIC USES THEREOF
#600Novel Control Switch